GENOR BIOPHARMA HLDGS LTDGENOR BIOPHARMA HLDGS LTDGENOR BIOPHARMA HLDGS LTD

GENOR BIOPHARMA HLDGS LTD

No trades
See on Supercharts
Market capitalization
‪592.22 M‬HKD
−1.47HKD
‪−745.17 M‬HKD
‪309.55 M‬
Beta (1Y)
0.68

About GENOR BIOPHARMA HLDGS LTD

CEO
Feng Guo
Headquarters
Shanghai
Employees (FY)
104
Founded
2007
ISIN
KYG3871A1004
FIGI
BBG00XC7TCX4
Genor Biopharma Holdings Ltd. engages in the development and commercialization of oncology and autoimmune drugs. The company was found on April 10, 2007 and is headquartered in Shanghai, China.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of 6998 is 1.17 HKD — it has increased by 0.86% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on HKEX exchange GENOR BIOPHARMA HLDGS LTD stocks are traded under the ticker 6998.
GENOR BIOPHARMA HLDGS LTD is going to release the next earnings report on Aug 28, 2024. Keep track of upcoming events with our Earnings Calendar.
6998 stock is 6.25% volatile and has beta coefficient of 0.68. Check out the list of the most volatile stocks — is GENOR BIOPHARMA HLDGS LTD there?
6998 earnings for the last quarter are −0.72 HKD per share, whereas the estimation was −0.55 HKD resulting in a −30.61% surprise. The estimated earnings for the next quarter are −0.62 HKD per share. See more details about GENOR BIOPHARMA HLDGS LTD earnings.
GENOR BIOPHARMA HLDGS LTD revenue for the last quarter amounts to ‪14.69 M‬ HKD despite the estimated figure of ‪7.97 M‬ HKD. In the next quarter revenue is expected to reach ‪4.32 M‬ HKD.
Yes, you can track GENOR BIOPHARMA HLDGS LTD financials in yearly and quarterly reports right on TradingView.
6998 stock has risen by 2.63% compared to the previous week, the last month showed zero change in price, over the last year GENOR BIOPHARMA HLDGS LTD has showed a 44.29% decrease.
6998 net income for the last quarter is ‪−431.93 M‬ HKD, while the quarter before that showed ‪−310.51 M‬ HKD of net income which accounts for −39.11% change. Track more GENOR BIOPHARMA HLDGS LTD financial stats to get the full picture.
Today GENOR BIOPHARMA HLDGS LTD has the market capitalization of ‪590.15 M‬, it has increased by 9.09% over the last week.
No, 6998 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, 6998 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade GENOR BIOPHARMA HLDGS LTD stock right from TradingView charts — choose your broker and connect to your account.
6998 reached its all-time high on Oct 7, 2020 with the price of 32.20 HKD, and its all-time low was 0.85 HKD and was reached on Feb 1, 2024.
See other stocks reaching their highest and lowest prices.
As of Apr 23, 2024, the company has 104.00 employees. See our rating of the largest employees — is GENOR BIOPHARMA HLDGS LTD on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So GENOR BIOPHARMA HLDGS LTD technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating GENOR BIOPHARMA HLDGS LTD stock shows the sell signal. See more of GENOR BIOPHARMA HLDGS LTD technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.